) is a Zacks #1 Rank (Strong Buy) after posting six consecutive
positive earnings surprises and recent accelerating earnings
Pharmerica Corporation operates as an institutional pharmacy
services company in the United States. It offers services to
healthcare facilities and provides management pharmacy services to
hospitals. Pharmerica Corporation operates approximately 95
institutional pharmacies in 44 states and provides pharmacy
management services to 91 hospitals. The company is headquartered
in Louisville, Kentucky.
PMC Exhibits Earnings Momentum
PMC has six consecutive positive earnings surprises. The company
reported earnings of $0.31 for the September 2011 quarter, $0.11 or
55% higher than expectations. The December 2011 quarter saw
earnings of $0.35, $0.14 ahead of the Zacks Consensus Estimate for
a 66% earnings beat.
The year before saw the company beat estimates, but it lacked the
dramatic increase in momentum that we saw in 2011. A beat of 10% in
the September 2010 quarter was followed up by a beat of 17% in
December 2010. The real difference was that EPS in September 2010
was $0.21, one penny more than the actual earnings in the December
PMC Recently Reported Earnings
On February 9, 2012 the company reported revenue of $496 million
roughly $4 million less than the Zacks Consensus Estimate but
higher than the $492 million reported in the year ago period. EPS
of $0.35 was $0.14 ahead of the Zacks Consensus estimate and higher
than the $0.20 reported in the year ago period.
Earnings Estimates Bumped Up
Following the most recent earnings report, analysts bumped up their
earnings estimates for 2012. The Zacks Consensus Estimate for 2012
EPS moved from $1.10 in January 2012 to the current level of $1.18.
PMC trades at very, very reasonable multiples. At 10x both trailing
and forward PE, the company trades at a discount to the industry
average for both multiples. The price to book multiple of 0.9x is
well below the 2.4x industry average and the price to sales metric
is also far below the industry average.
Looking at the chart we see the stock has found some base line
support that has been tested three times. The support line can be
drawn in at the lows reached in early February, retested in early
March and again in late March. A break out for this stock will be
driven by real revenue growth and could get this stock back to
previous highs, which are 33% above current levels. PMC is a Zacks
#1 Rank (Strong Buy).
Brian Bolan is the Aggressive Growth Stock Strategist for
Zacks.com. He is also the Editor in charge of the
Run Investor service
PHARMERICA CORP (
): Free Stock Analysis Report
To read this article on Zacks.com click here.